ライフサイエンスコーパス: beta-gal

1 beta-gal cDNA-transduced keratinocytes did not demonstra

2 beta-gal staining in all lines followed a similar patter

3 beta-gal+ cells in TIE2-LacZ vessels grafted to Balb/c m

4 beta-gal-positive cells expressing mesenchymal markers a

5 Interestingly, 35+/-19% beta-gal+ cells were found in arterial segments allograf

6 se DOME homo-dimerisation, we have applied a beta-gal complementation technique that allows the detec

7 Using this substrate, we developed a beta-gal activity assay method.

8 row cells, a proportion of cells displayed a beta-gal+ staining.

9 ells of microvessels within allografts had a beta-gal+ staining in the media at 1 week and in the neo

10 and p75, on intact mammalian cells, using a beta-gal protein-protein interaction system.

11 In nucleus accumbens, beta-gal was expressed in several major subpopulations o

12 ical markers of senescence, including acidic beta-gal staining, induction of p16INK4a, and p15INK4b e

13 showed intracellular accumulation of active beta-gal.

14 adenovirus expressing beta-galactosidase (Ad-beta gal)-transfected macrophages and produced elevated

15 r LEW kidneys were perfused with Ad-HO-1, Ad-beta-gal, or PBS, stored at 4 degrees C for 24 h, and tr

16 e groups [group 1: no treatment, group 2: Ad-beta-gal, group 3: AdvIL-10, group 4: CsA (10 mg/kg), an

17 tio at day 7 was elevated in both PBS and Ad-beta-gal, as compared with the Ad-HO-1 group (12.0 and 9

18 val advantage when compared with PBS- and Ad-beta-gal-treated controls, with median survival of 100,

19 ovirus that expresses beta-galactosidase (Ad-beta-gal) was used.

20 vIL-10 (Ad-vIL-10) or beta-galactosidase (Ad-beta-gal) were derived from adenovirus type 5.

21 and glomerulosclerosis was more severe in Ad-beta-gal group at all time points.

22 val of liver grafts increased from 50% in Ad-beta-gal untreated controls to 100% after Ad-IL-13 gene

23 red either adenovirus Ang-1 (Ad-Ang-1) or Ad-beta-gal systemically immediately after ligation of the

24 Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p

25 plant in the Ad-HO-1 group, compared with Ad-beta-gal controls (P < 0.05); tubular HO-1 expression wa

26 as 16 +/- 5 episodes per h (n = 6) in the Ad.beta gal group, 22 +/- 6 in the Ad.PV group, and 4 +/- 2

27 coding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

28 Ad.Kv4.3) or the beta-galactosidase gene (Ad.beta-gal).

29 eatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanc

30 ely (P<0.05) in AS myocytes infected with Ad.beta-gal compared with sham myocytes.

31 AS rats infected with Ad.beta-gal developed cardiac hypertrophy compared with sha

32 y density compared with pigs treated with Ad.beta-gal was found at 3 months and suggests an angiogeni

33 ed by 4.2% (P=0.004) in pigs treated with Ad.beta-gal.

34 odified fiber protein and infection with Ad5.beta gal.Delta F, an E1-, E3-, and fiber-deleted adenovi

35 nsgenes for either beta-galactosidase (adeno-beta-gal, n=11) or the human beta(2)-adrenergic receptor

36 ene expression among animals receiving adeno-beta-gal.

37 DTH response and proliferation assays after beta-gal immunization.

38 All beta-gal-positive cells exhibited abundant cytoplasm, a

39 ve cells within injured lungs was nearly all beta-gal-positive, indicating epithelial cells as the ma

40 vel, in the central nucleus of the amygdala, beta-gal was found in cells both with and without mu opi

41 H decrease of 3.1 and 2.7 units (for BSA and beta-gal, respectively) attributed to selective crystall

42 binding inhibited receptor dimerization and beta-gal complementation.

43 th methylprednisolone and antibodies, EA and beta-gal were detected, and replicating virus was recove

44 not differ between the FGF-2-fibroblast and beta-gal-fibroblast groups.

45 roblasts, we implanted FGF-2-fibroblasts and beta-gal-fibroblast into the striatum of rats but did no

46 nd isolated cells were evaluated for GFP and beta-gal as well as expression of alpha-smooth muscle ac

47 from untreated liver expressed both GFP and beta-gal with a fibroblast-like morphological change but

48 s never showed double-positivity for GFP and beta-gal.

49 of medium to large proteins (HRP, 44 kDa and beta-gal, 465 kDa) and antibodies (ca. 150 kDa).

50 -associated heterochromatic foci (SAHF), and beta-gal staining.

51 ssessed the retinal location of ANT and ANT1-beta-gal reporter protein, mitochondrial activity with c

52 rocessing and presentation using an antigen (beta-gal) that was either applied to or expressed in RPE

53 chimeric receptor dimerization detectable as beta-gal enzymatic activity.

54 ted open reading frames (ORFs) translated as beta-gal chimeras are selected as a candidate pool of po

55 ding growth arrest and senescence-associated beta-gal (SA-beta-gal) activity.

56 active AMPK increased senescence-associated beta-gal activity, whereas infection with an adenovirus

57 egative AMPK decreased senescence-associated beta-gal activity.

58 c markers such as p16, senescence-associated beta-gal, and gammaH2AX, in addition to more recent mark

59 al tolerance was assessed by placement of B6 beta-gal transgenic (tg) and third-party skin grafts.

60 y prevented the induction of tolerance to B6 beta-gal tg skin grafts.

61 in chimeric mice expressing GFP or bacterial beta-gal or harboring the male Y chromosome exclusively

62 innocuous or self-specific knocked in BCRs, beta-gal was preferentially expressed in pre-B cells fro

63 ic factor (BDNF)LacZ mice reveals that BDNF (beta-gal) and trkB colocalize, mainly in type III taste

64 f, reveal an unambiguous correlation between beta-gal activity and the solubility/folding of the targ

65 d a marked increase in cells expressing both beta-gal, indicating bone marrow origin and Tie-2 expres

66 were >100-fold higher than those afforded by beta-gal- B cells following adoptive transfer to naive h

67 in awake, alert animals were not altered by beta-gal or wtGi.

68 actoside conjugate, must first be cleaved by beta-gal before it can be catalyzed by firefly luciferas

69 galactopyranoside (DDAOG), can be cleaved by beta-gal to produce 7-hydroxy-9H(I,3-dichloro-9,9-dimeth

70 d to the inhibitory molecule daunorubicin by beta-gal.

71 t loss of endothelial cells was evidenced by beta-gal staining for vein grafts in transgenic mice exp

72 pyranoside (OFPNPG) is readily hydrolyzed by beta-gal with a corresponding decrease in the 19F-NMR si

73 yte-derived cells are permanently labeled by beta-gal and type I collagen-expressing cells are labele

74 ic manipulation primed a population of CD4+, beta-gal-specific, TGFbeta-producing T cells.

75 ease in the number of double-positive cells (beta-gal, isolectin B4) on the luminal surface in caroti

76 din-2-one) (DDAO), is not only a chromogenic beta-gal substrate but that the cleavage product has far

77 Using chromogenic beta-gal substrates, HCMV was detected during MK differe

78 Akt gene, or with the control vector Ad.CMV-beta-gal, which expresses beta-galactosidase.

79 Using this technology, constitutive beta-gal activity in engineered cells and inducible tiss

80 Conversely, beta-gal+ cells were observed on the surface of vein seg

81 sistent with our model of opiate dependence, beta-gal expression increased in the LC, but decreased i

82 r architectures to create agents that detect beta-gal activity by modulating the coordination of wate

83 pe controls, which coincided with diminished beta-gal+ endothelial cells on the surface of vein graft

84 es with excellent performance for endogenous beta-gal detection offer a unique option for visualizati

85 In contrast, LECs do not present endogenous beta-gal in the context of MHC-II molecules to beta-gal-

86 geting ability, Lyso-Gal realizes endogenous beta-gal visualization in lysosomes and shows brighter f

87 Mice that express beta-gal in the retina and various control mice were imm

88 some tubular cells also appeared to express beta-gal as assessed by X-gal staining, but following su

89 of twelve founder mice were found to express beta-gal in podocytes (33% penetrance).

90 pproximately 20% of secondary AFCs expressed beta-gal.

91 of twlve NPHS2 mouse founder lines expressed beta-gal exclusively in podocytes (100% penetrance).

92 VTA and DRN the majority of cells expressing beta-gal were nonmonoaminergic.

93 enzyme activity in a mouse model expressing beta-gal.

94 that were previously made tolerant to female beta-gal tg skin were rapidly rejected, however, suggest

95 ssion and generated a fusion protein (FGF14N-beta-gal) containing the first exon of FGF14 and beta-ga

96 Strikingly, the FGF14N-beta-gal chimeric protein was efficiently transported in

97 g mice producing CD4(+) T cells specific for beta gal (beta galTCR).

98 s did not occur in mice double deficient for beta-gal and ganglioside synthase, beta-gal-/-/GalNAcT-/

99 of the P2 OR subtype via immunostaining for beta-gal and concurrent OMP or GAP-43 expression in P2-I

100 of RPE with resting CD8 T cells specific for beta-gal.

101 ion experiments showed that the newly formed beta-gal(+) SMC were not derived from circulating bone m

102 Furthermore, beta-gal expression demonstrates a lineage relationship

103 c (Tg) for expression of beta-galactosidase (beta gal) on the retinal photoreceptor cell arrestin pro

104 A2a or the reporter gene beta-galactosidase (beta gal) or parvalbumin (PV), as early as 48 h before a

105 sion of genes coding for beta galactosidase (beta-gal), enhanced green fluorescent protein (EGFP), va

106 ly engineered to produce beta-galactosidase (beta-gal) (n=8) or FGF-2 (n=8), at two sites in the righ

107 of senescence-associated beta-galactosidase (beta-gal) activity and increased p16INK4a expression.

108 expression by assessing beta-galactosidase (beta-gal) activity in vivo.

109 ed the ability to detect beta-galactosidase (beta-gal) activity on the basis of 19F NMR chemical shif

110 0.09-fold (n = 4) higher beta-galactosidase (beta-gal) activity than N. meningitidis 5'lst::lacZ fusi

111 for in vivo detection of beta-galactosidase (beta-gal) activity.

112 beta-galactosidase (beta-gal) and beta-glucuronidase (beta-glucur) are both

113 or an irrelevant protein beta-galactosidase (beta-gal) as the control, induced to undergo apoptosis,

114 into the procedure with beta-galactosidase (beta-gal) as the detection enzyme.

115 ruitment domain (ARC) or beta-galactosidase (beta-gal) cDNA into the pTAT-hemagglutinin bacterial exp

116 denovirus containing the beta-galactosidase (beta-gal) cDNA, triacylglycerols in the liver and plasma

117 deficiency of lysosomal beta-galactosidase (beta-gal) characterizes the neurodegenerative disease GM

118 to weakly complementing beta-galactosidase (beta-gal) deletion mutants were expressed in cells in cu

119 o HC-Ad vectors encoding beta-galactosidase (beta-gal) driven by a TetOn system containing the rtTAS(

120 for EMT, mice expressing beta-galactosidase (beta-gal) exclusively in lung epithelial cells were gene

121 ogenous Escherichia coli beta-galactosidase (beta-gal) expressed through a retinal arrestin promoter.

122 and cellular mapping of beta-galactosidase (beta-gal) expression during naltrexone-precipitated with

123 mice were generated and beta-galactosidase (beta-gal) expression was analyzed.

124 sion of an axon-targeted beta-galactosidase (beta-gal) from such vectors supports mapping specific co

125 used to release endemic beta-galactosidase (beta-gal) from the bound bacterial cells; (3) the releas

126 murine VEGF gene and the beta-galactosidase (beta-gal) gene from a retroviral promoter were implanted

127 beta-Galactosidase (beta-gal) has been widely used as a transgene reporter e

128 se animals, staining for beta-galactosidase (beta-gal) identifies cells in which NF-kappaB has been a

129 In these mice, beta-galactosidase (beta-gal) immunoreactivity is an indicator of cells that

130 lubilize heat-aggregated beta-galactosidase (beta-gal) in the absence of the Hsp70 system.

131 beta-Galactosidase (beta-gal) is commonly used as a reporter gene in biologi

132 We demonstrate that when beta-galactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T

133 nant adenovirus encoding beta-galactosidase (beta-gal) or alpha(s)* was applied to arterial segments

134 cells, which are either beta-galactosidase (beta-gal) positive or beta-gal negative.

135 g the SM22alpha promoter-beta-galactosidase (beta-gal) reporter transgene were crossed to apolipoprot

136 he M9PROM was fused to a beta-galactosidase (beta-gal) reporter.

137 roduced progeny in which beta-galactosidase (beta-gal) was permanently expressed in B cells of the GC

138 e expressing ROSA26 stop beta-galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) green flu

139 ith hen egg lysozyme and beta-galactosidase (beta-gal), demonstrating adaptive immune responses again

140 novirus (rAd.A20) or rAd.beta-galactosidase (beta-gal), implanted, harvested 4 weeks after transplant

141 beta-Galactosidase (beta-gal), one of the typical lysosomal glycosidases, is

142 control group expressing beta-galactosidase (beta-gal), respectively.

143 r early antigen (EA) and beta-galactosidase (beta-gal), respectively.

144 um albumin (BSA) and ii) beta-galactosidase (beta-gal), was investigated by micro-flow imaging (MFI)

145 th adenoviruses encoding beta-galactosidase (beta-gal), wild-type Galpha(i2) (wtGi), or constitutivel

146 challenged mice with the beta-galactosidase (beta-gal)-expressing tumor cells, C25.F6, vaccinated the

147 e, and the prevalence of beta-galactosidase (beta-gal)-positive cells was determined, indicative of C

148 blastocysts with p63+/+ beta-galactosidase (beta-gal)-positive ES cells, we show that secretory cell

149 lowed by the addition of beta-galactosidase (beta-gal)-specific CTLs.

150 mouse models expressing beta-galactosidase (beta-gal).

151 deficiency of lysosomal beta-galactosidase (beta-gal).

152 antibodies conjugated to beta-galactosidase (beta-gal).

153 lacZ operon encoding for beta-galactosidase (beta-gal).

154 and omega- fragments of beta-galactosidase (beta-gal).

155 ce were made tolerant to beta-galactosidase (beta-gal).

156 sses the omega-domain of beta-galactosidase (beta-gal).

157 duces protein fusions to beta-galactosidase (beta-gal); non-annotated open reading frames (ORFs) tran

158 Dlx2/tauLacZ [beta-galactosidase (beta-gal)]-expressing cells populate the central SVZ, wh

159 Lysosomal beta-D-galactosidase (beta-gal), the enzyme deficient in the autosomal recessi

160 n increased expression of beta-galactosidase(beta-gal) plasmid in rat brain tissue in comparison to t

161 TAT-HA-beta-gal was also transduced into cells in all regions o

162 Transduction of TAT-HA-beta-gal was detected by X-gal staining.

163 proteins, TAT-HA-beta-galactosidase (TAT-HA-beta-gal), TAT-HA-myocilin, and TAT-HA-myocilin-EGFP.

164 tor and/or upon boosting with a heterologous beta-gal-carrying virus.

165 ngliosidosis patients with recombinant human beta-gal (rhbeta-gal) produced in Chinese hamster ovary

166 nly if prepulsed with cognate peptide, or if beta-gal-expressing RPE was pretreated to induce upregul

167 The ability to image beta-gal expression in living animals would further exte

168 In beta-gal chimeras, some tubular cells also appeared to e

169 d that IRF4 transcripts were up-regulated in beta-gal(+) pre-B cells.

170 ol place conditioning, we observed increased beta-gal staining in the nucleus accumbens (NAC) shell a

171 bone marrow transplantation showed increased beta-gal activity in different brain regions and reduced

172 In addition, withdrawal increased beta-gal expression in the continuum of the extended amy

173 The endogenous and phage-induced beta-gal was detected using the electrochemical method w

174 l as bone marrow macrophages, showed intense beta-gal histo- or cytostaining in adult noggin+/- mice

175 Interestingly, beta-gal+ cells were evenly distributed on the surface o

176 (2) release of the endogenous intracellular beta-gal from E. coli following infection.

177 IkappaB alpha gene was replaced with a lacZ (beta-gal) reporter complementary DNA (cDNA; IkappaB alph

178 In LC, beta-gal expression was induced predominantly in tyrosin

179 lactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells undergo deletion via the P

180 ypomorphic mice expressing a promoter-linked beta-gal reporter to show that inflammatory colitis supp

181 hicken gamma globulin showed that long-lived beta-gal+ B cells exclusively contained somatically muta

182 actosidase beta1 (GLB1) gene cause lysosomal beta-gal deficiency, resulting in accumulation of galact

183 argeting ability was developed for lysosomal beta-gal detection and imaging in ovarian cancer cells (

184 We cloned VLRB binders of lysozyme, beta-gal, cholera toxin subunit B, R-phycoerythrin, and

185 Second male beta-gal tg grafts placed onto female recipients that we

186 lowing suppression of endogenous (mammalian) beta-gal, no tubular cells could be found that stained w

187 In the tongues of adult BDNF(LacZ) mice, beta-gal (BDNF) is present in long slender taste cells,

188 aracterized by a large flat cell morphology, beta-gal staining and irreversible loss of regenerative

189 of rhbeta-gal was sufficient for normalizing beta-gal activity and mediating substrate clearance for

190 Application of alpha(s)*, but not beta-gal containing adenovirus, inhibited formation of n

191 R T cells in mice with retinal expression of beta gal and inhibited the ear-swelling assay for delaye

192 go senescence as indicated by the absence of beta-gal activity and p16(INK4a) tumor suppressor expres

193 A substantial advantage of beta-gal as a bioluminescent probe is that the enzyme re

194 the properties of FLuc to the advantages of beta-gal permits bioluminescent imaging applications tha

195 The RF scar area and the area of beta-gal staining were measured and normalized to LV are

196 ndicated that in vivo real-time detection of beta-gal activity is possible by fluorescence imaging te

197 t vessels displayed a unique distribution of beta-gal+ cells on the surface at 3 days, 1 week, and 4

198 h level of expression of the omega-domain of beta-gal in the model K12 strains allowed us to detect,

199 r the N-terminal or the C-terminal domain of beta-gal resulted in the synthesis of correctly sized po

200 response increased with increasing doses of beta-gal-carrying vector and/or upon boosting with a het

201 lt of this complementation-an active form of beta-gal-was detected colorimetrically, and the high lev

202 Intravenous injection of beta-gal induced true immunologic tolerance to beta-gal

203 and underlying media showed complete loss of beta-gal activity in advanced atherosclerotic lesions.

204 The majority of beta-gal+ cells present in the allografts exhibited fibr

205 otid artery of wild-type mice, the number of beta-gal+ cells were reduced at 3 days and disappeared c

206 evealed a 2.9-fold increase in the number of beta-gal-positive cells per square millimeter appearing

207 the ability to trigger the overexpression of beta-gal during the infection of E. coli.

208 etection of E. coli by (1) overexpression of beta-gal in E. coli during the specific infection and (2

209 neurospheres recapitulated the phenotype of beta-gal-/- cells and activated this pathway by depletin

210 aused accumulation of a prelysosomal pool of beta-gal, resulting in activation of the unfolded protei

211 hanges from yellow to red in the presence of beta-gal.

212 pulmonary PW1(+) cells and the proportion of beta-gal(+) vascular SMC were increased, indicating a re

213 he bound bacterial cells; (3) the release of beta-gal was detected using chlorophenol red-beta-d-gala

214 eporter assay system for the wide variety of beta-gal systems currently in use.

215 As a result, luminescence is dependent on beta-gal activity.

216 adenovirus encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area

217 ure was found, which showed beta-gal/CD31 or beta-gal/von Willebrand factor double positivity.

218 cence with antibodies against GFP, DsRed, or beta-gal using the method of immunolabeling-enabled thre

219 the groups that received a burr hole only or beta-gal-fibroblasts at weeks 2 and 3 following lesionin

220 er beta-galactosidase (beta-gal) positive or beta-gal negative.

221 sites of diverse enzymes from the peptidase, beta-gal, and nucleotide synthase families.

222 ystem together with a bifunctional 6-phospho-beta-gal/glucosidase, Gan1D.

223 ccessful implantation of myoblasts (positive beta-gal reaction product) in 6 of 6 surviving experimen

224 on to beta-gal96-103 significantly prolonged beta-gal transgenic skin graft survival, confirming its

225 prevented the decrease in SM22alpha promoter-beta-gal reporter transgene expression, including in cel

226 LacZ gene expression of the protein beta-gal was demonstrated as early as 1 hour, with expre

227 llowing isolation, using R26R-EYFP and R26R (beta-gal) reporter mice, respectively.

228 levels in nontransduced, and rAd.A20 or rAd.beta-gal-transduced human SMC cultures after cytokine tr

229 lt, antibodies conjugated to the recombinant beta-gal enzyme can be used to detect endogenous cells a

230 t mice expressing a cardiomyocyte-restricted beta-gal reporter gene.

231 of CD25(-) beta galTCR T cells into retinal beta gal Tg mice on the Rag(-/-) background led to regul

232 y CD3(+)4(+)25(+) T cells from naive retinal beta gal(+) donors.

233 Endogenous retinal beta-gal expression depressed the DTH response and proli

234 Senescence-associated beta-galactosidase (SA beta-gal) activity was observed in lymphomas from Emu-my

235 senescence-associated beta-galactosidase (SA beta-gal) activity, apparently irreparable genomic DNA b

236 p16(Ink4a), p21, senescence-associated (SA) beta-gal activity, and SA secretion of proinflammatory c

237 rs of cellular senescence, p16(Ink4a) and SA-beta-gal.

238 ed bone marrow progenitor cells expressed SA-beta-gal and senescence-associated proteins p53 and p21(

239 is and senescence, tested as staining for SA-beta-gal, also expressed p16(INK4A).

240 escence induction, tested as staining for SA-beta-gal, in reoxygenated progenitor cells was closely c

241 rrest and senescence-associated beta-gal (SA-beta-gal) activity.

242 senescence-associated beta-galactosidase (SA-beta-gal) activation, and increased mRNA expression of a

243 senescence-associated beta-galactosidase (SA-beta-gal) activity and production of intracellular react

244 senescence-associated beta-galactosidase (SA-beta-gal) activity but an increase in adenosine triphosp

245 en species (iROS), SA-beta-galactosidase (SA-beta-gal) activity, and autofluorescence (AF) was assess

246 ameter) anti-PECAM/SA-beta galactosidase (SA-beta-gal) conjugates bound selectively to PECAM-expressi

247 ed as staining for SA-beta-galactosidase (SA-beta-gal), of bone marrow progenitor cells.

248 senescence-associated beta-galactosidase (SA-beta-gal), p16Ink4a, and p53 in lamin A/C-deficient musc

249 senescence-associated beta-galactosidase (SA-beta-gal).

250 With age, NSCs exhibited increased SA-beta-gal activity and decreased proliferation and pool s

251 ditions and significantly decreased iROS, SA-beta-gal, and AF normally induced by hyperoxic condition

252 enhanced expression of senescent markers SA-beta-gal, PML, and p16(INK4a).

253 over, inhibition of ATM signaling reduced SA-beta-gal positivity but increased apoptosis of reoxygena

254 llary-like structure was found, which showed beta-gal/CD31 or beta-gal/von Willebrand factor double p

255 Blue X-gal staining, signifying beta-gal activity resulting from transduction, was obser

256 xpression was also confirmed both by in situ beta-gal staining and quantitative enzymatic activity as

257 Sorted beta-gal(+) pre-B cells showed increased levels of vario

258 gineered cells and inducible tissue-specific beta-gal expression in transgenic mice can now be visual

259 senescence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression.

260 cient for beta-gal and ganglioside synthase, beta-gal-/-/GalNAcT-/-, which do not accumulate GM1.

261 t germ agglutinin (WGA) and an axon-targeted beta-gal supports mapping both specific projections of t

262 TAT-beta-gal and TAT-ARC readily transduced into perfused he

263 TAT-beta-gal and TAT-ARC were conjugated with Texas Red and

264 r to produce genetic in-frame TAT-ARC or TAT-beta-gal fusion proteins for use in cell culture and in

265 lt hearts were perfused with recombinant TAT-beta-gal or TAT-ARC (20 nmol/L) for 15 minutes and then

266 t studies in chimeric mice demonstrated that beta-gal+ cells of microvessels in transplant arterioscl

267 polymerase chain reaction, it was found that beta-gal(+) cells were mainly expressing CD31 and CD144.

268 Specifically, we show that beta-gal-expressing 9L gliomas are readily detectable by

269 Our results suggest that beta-gal-expressing bone marrow (BM)-derived cells selec

270 Experiments that removed the beta gal(+) retina by enucleation showed that subsequent

271 The beta-gal catalyzed PAPG to an electroactive species p-am

272 The beta-gal/DDAOG assay method should provide a fluorescent

273 The beta-gal/DDAOG assay method was also tested in transient

274 An optimized buffer for the beta-gal/DDAOG assay was also formulated.

275 ) promoter (COL1A2) cloned upstream from the beta-gal reporter gene were injected with carbon tetrach

276 In the beta-gal group, cardiomyopathy worsened over time.

277 eart transplant resulted in migration of the beta-gal+ cells into the lesions of chronic rejection in

278 same number of myoblasts expressing only the beta-gal gene.

279 Here, we show, using the beta-gal gene as a reporter, that amber, ochre, and opal

280 memory CD8+ T cells are contained within the beta-gal-marked CD8+ T cell population.

281 M9PROM activation was localized through beta-gal staining.

282 depressed development of immune responses to beta gal following systemic immunization with beta gal.

283 (19.6 vs. 12 days, P<0.001) when compared to beta-gal transfected controls.

284 rAAV5betagal intrastriatal injections led to beta-gal-positive parenchymal cells, but, unlike rAAV2be

285 ta-gal in the context of MHC-II molecules to beta-gal-specific CD4 T cells.

286 Provision of whole beta-gal, as opposed to beta-gal peptide, gave no evidence of T-cell activation.

287 cluding highly sensitive 19F NMR response to beta-gal activity (Deltadelta=9.0 approximately 9.4 ppm)

288 ta-gal induced true immunologic tolerance to beta-gal tg skin in wild-type but not in B-cell-deficien

289 Importantly, LECs transfer beta-gal to dendritic cells, which subsequently present

290 ion of primary ovarian cancer cells by using beta-gal as the biomarker.

291 f total cells in the lesion-prone areas were beta-gal positive in apoE(-/-) with apoE(-/-)/TIE2-LacZ

292 Provision of whole beta-gal, as opposed to beta-gal peptide, gave no eviden

293 eta gal following systemic immunization with beta gal.

294 lurp1(-/-)) created by replacing exon 2 with beta-gal and neo cassettes.

295 MAPK staining in the intima as compared with beta-gal-treated vessels.

296 ondary AFCs showed a strong correlation with beta-gal expression, suggesting that nonmutated B cells

297 and various control mice were immunized with beta-gal and tested for immune responsiveness by the ear

298 fluorescence at 725 nm after incubation with beta-gal.

299 -galactopyranoside (CPRG), which reacts with beta-gal to produce chlorophenol red (CPR) in a bacteria

300 ng tumor cells, C25.F6, vaccinated them with beta-gal-carrying viral vectors, and used quantitative R